Drug profile · INN
efbemalenograstim alfa
RYZNEUTA
efbemalenograstim alfa (RYZNEUTA) is a granulocyte colony stimulating factor receptor agonist.
EMA: approved Antineoplastic and immunomodulating agents (L03) L03AA18
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — efbemalenograstim alfa
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
efbemalenograstim alfa (RYZNEUTA) is a granulocyte colony stimulating factor receptor agonist.
Key facts
INN efbemalenograstim alfa
Brand RYZNEUTA
Mechanism Granulocyte colony stimulating factor receptor agonist
Target Granulocyte colony-stimulating factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L03)
ATC code L03AA18
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is efbemalenograstim alfa?
efbemalenograstim alfa (RYZNEUTA) is a granulocyte colony stimulating factor receptor agonist.
What is the brand name for efbemalenograstim alfa?
RYZNEUTA is a marketed brand name for efbemalenograstim alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.